...

A Phase 1, Open-Label, Multicenter Study of KYV-101-001, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis

To test CAR T cell therapy (a type of therapy made from one's own immune cells) for refractory lupus nephritis


Why this Research Matters

Apheresis (collection of white blood cells) followed by lymphodepletion (medications to weaken, temporarily, your immune system so that the CAR T cells can grow and work in the body, followed by single infusion of KYV-101 (the CAR T cells made specifically for your body)


Who can Participate

Adult

* age of 18 or older * lupus nephritis that has not responded to other therapies * clinical diagnosis of SLE * active, biopsy-proven, proliferative lupus nephritis class III or IV * inadequate response (urine protein equal to or greater than 1.5 g/24 hrs after at least 6 months of treatment with 2 or more conventional therapies * up to date on vaccinations, including against COVID-19 * not pregnant


Study ID

Protocol Number: 22-1850
More information available at ClinicalTrials.gov: NCT05938725

Meet the Team

Image of Principal Investigator

Amber Podoll, MD

Principal Investigator